Chiorean, E. Gabriela

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine

Pancreatic and Hepatic Oncology ResearchCancer Treatment and Pharmacology

Cited by 6,712

Phase IB/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313

Ramanathan, R. K., McDonough, S. L., Philip, P. A., Hingorani, S. R., Lacy, J., Kortmansky, J. S., Thumar, J., Chiorean, E. G., Shields, A. F., Behl, D., et al. (2019) · Journal of Clinical Oncology

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 336

Neoadjuvant Selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer

Byrne, K. T., Betts, C. B., Mick, R., Sivagnanam, S., Bajor, D. L., Laheru, D. A., Chiorean, E. G., O'Hara, M. H., Liudahl, S. M., Newcomb, C., et al. (2021) · Clinical Cancer Research

Pancreatic and Hepatic Oncology ResearchCancer Immunotherapy and Biomarkers

Cited by 199

Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer

Borad, M. J., Reddy, S. G., Bahary, N., Uronis, H. E., Sigal, D., Cohn, A. L., Schelman, W. R., Stephenson, J., Chiorean, E. G., Rosen, P. J., et al. (2015) · Journal of Clinical Oncology

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 197

KRAS Mutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal Adenocarcinomas

Diehl, A. C., Hannan, L. M., Zhen, D. B., Coveler, A. L., King, G., Cohen, S. A., Harris, W. P., Shankaran, V., Wong, K. M., Green, S., et al. (2022) · The Oncologist

Pancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics

Cited by 35

EZN-2968, a novel hypoxia-inducible factor-1α (HIF-1α) messenger ribonucleic acid (mRNA) antagonist: Results of a phase I, pharmacokinetic (PK), dose-escalation study of daily administration in patients (pts) with advanced malignancies

Patnaik, A., Chiorean, E. G., Tolcher, A., Papadopoulos, K., Beeram, M., Kee, D., Waddell, M., Gilles, E., & Buchbinder, A. (2009) · Journal of Clinical Oncology

Cancer, Hypoxia, and MetabolismAngiogenesis and VEGF in Cancer

Cited by 26

Phase I study of REGN421 (R)/SAR153192, a fully‐human delta‐like ligand 4 (Dll4) monoclonal antibody (mAb), in patients with advanced solid tumors

Jimeno, A., LoRusso, P., Strother, R. M., Diamond, J. R., Plato, L., Younger, A., Messersmith, W. A., Kittaneh, M., Sawyer, D., Adriaens, L., et al. (2013) · Journal of Clinical Oncology

Angiogenesis and VEGF in CancerCancer Immunotherapy and Biomarkers

Cited by 15